Q-omics provides the consensus-scored GPR21 profile across patient tissues and cancer cell-line models. GPR21 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GPR21 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, GPR21 RNA expression shows 17,428 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where GPR21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPR21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPR21 survival associations across molecular data types. GPR21 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPR21 RNA expression–survival associations across cancer types. High GPR21 expression shows unfavorable associations in KIRP, BRCA and LUAD, but favorable associations in KIRC, UCS and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GPR21 RNA expression.
This table summarizes GPR21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GPR21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPR21 shows lower tumor expression in UCEC, KICH and LUSC and higher tumor expression in KIRC, BRCA and LIHC. The KIRC box plot shows higher GPR21 RNA expression in tumor versus normal tissue (log2 FC = +0.089, t-test p < 0.001).
This table shows molecular features associated with GPR21 in patient tissues and cancer cell lines. In patient samples, GPR21 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPR21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
